[144] Protagonist Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. (PTGX) filing of Form 144 notifies a proposed sale of 4,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 08/27/2025. The shares were acquired on 05/03/2022 via previously exercised stock options and paid in cash. The filing reports an aggregate market value of $227,960.00 for the shares to be sold and indicates 62,211,318 shares outstanding for the issuer. The filer certifies they are not aware of undisclosed material adverse information and states no sales by the filer in the past three months.

Insights

Financial Analyst

TL;DR: Routine insider sale of 4,000 shares; size is immaterial relative to outstanding stock, so limited market impact.

The transaction represents a sale of 4,000 shares valued at approximately $227,960, representing roughly 0.0064% of the reported 62,211,318 outstanding shares. The shares were acquired by exercising options on 05/03/2022, paid in cash, and are to be sold via Morgan Stanley Smith Barney LLC on NASDAQ around 08/27/2025. From a financial-materiality perspective, this disposition amount is small and unlikely to affect liquidity, earnings, or valuation metrics at scale.

Corporate Governance Expert

TL;DR: Standard Form 144 disclosure; presents required certification but shows no recent insider sales.

The filing follows Rule 144 disclosure norms and includes the filer's attestation of no undisclosed material adverse information. It lists no securities sold by the filer in the past three months, suggesting this is an isolated, pre-notified sale rather than part of an ongoing large disposition. Governance-wise, the document meets procedural requirements and contains the broker, acquisition method (previously exercised options), and payment details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4000	227960.00	62211318	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/03/2022	Previously Exercised Stock Options	Issuer			4000	05/03/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the PTGX Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 4,000 common shares via Morgan Stanley Smith Barney LLC on NASDAQ, approx. date 08/27/2025, aggregate value $227,960.00.

How and when were the PTGX shares being sold acquired?

The shares were acquired on 05/03/2022 through previously exercised stock options and were paid for in cash on that date.

How many PTGX shares are outstanding according to the filing?

The filing reports 62,211,318 shares outstanding for the issuer.

Did the filer report other sales of PTGX in the past three months?

No. The section for securities sold during the past three months states Nothing to Report.

What certification does the filer make in this Form 144?

The filer represents that they do not know of any material adverse information about the issuer that has not been publicly disclosed and provides the required signature attestation.